Cormorant Pharmaceuticals AB
Records under this name other than patents Cormorant Pharmaceuticals AB holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 7 of 7 · Back to Cormorant Pharmaceuticals AB
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,066,012 | Human Monoclonal Antibodies Against Interleukin 8 (IL-8) Term ended Ended no later than Aug 28, 2024 · Medium confidence | Term ended | Ended no later than Aug 28, 2024 | Medium confidence |
| US 7,282,568 | Human Monoclonal Antibodies Against Interleukin 8 (IL-8) Term ended Term ended May 13, 2024 · High confidence | Term ended | Term ended May 13, 2024 | High confidence |
| US 7,622,559 | Human Monoclonal Antibodies Against Interleukin 8 (IL-8) Term ended Ended no later than Dec 16, 2023 · Medium confidence | Term ended | Ended no later than Dec 16, 2023 | Medium confidence |
| US 8,105,588 | Human Monoclonal Antibodies Against Interleukin 8 (IL-8) Term ended Term ended Dec 16, 2023 · High confidence | Term ended | Term ended Dec 16, 2023 | High confidence |
| US 8,603,469 | Methods of Treating Cancer with Human Monoclonal Antibodies Against Interleukin 8 Term ended Term ended Dec 16, 2023 · High confidence | Term ended | Term ended Dec 16, 2023 | High confidence |
| US 10,253,093 | Human Monoclonal Antibodies Against Interleukin 8 (IL-8) Term ended Term ended Dec 16, 2023 · Medium confidence | Term ended | Term ended Dec 16, 2023 | Medium confidence |
| US 11,339,215 | Methods of Treating Cancer with Human Monoclonal Antibodies Against Interleukin 8 (IL-8) Term ended Term ended Dec 16, 2023 · High confidence | Term ended | Term ended Dec 16, 2023 | High confidence |